Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Ph II Study of Perifosine for Patients With Carcinoma of the Kidney

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AEterna Zentaris
ClinicalTrials.gov Identifier:
NCT00498966
First received: July 9, 2007
Last updated: February 14, 2014
Last verified: November 2011
  Purpose

This is a Phase II study. Patients with kidney carcinoma will be considered in two groups. The goals of this study are:

  • To measure clinical benefit defined as tumor response or progression-free survival for more than 12 weeks in patients with metastatic carcinoma of the kidney who have failed or have progressed on a VEGF receptor inhibitor
  • To evaluate the safety of perifosine in patients with metastatic carcinoma of the kidney who have failed or have progressed on a VEGF receptor inhibitor

Condition Intervention Phase
Kidney Cancer
Drug: Perifosine
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Perifosine for Patients With Metastatic Carcinoma of the Kidney Who Have Progressed on a VEGF Receptor Inhibitor

Resource links provided by NLM:


Further study details as provided by AEterna Zentaris:

Primary Outcome Measures:
  • Objective tumor response using RESIST OR progression-free survival [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Evaluate the safety of perifosine in patients with metastatic carcinoma of the kidney [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 50
Study Start Date: July 2007
Study Completion Date: October 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Perifosine 100 mg PO
Drug: Perifosine
Perifosine 100 mg PO

Detailed Description:

This is a Phase II study. Patients with kidney carcinoma will be considered in two groups. Patients in group A will have previously failed a VEGF receptor inhibitor but not an mTOR inhibitor, while patients in group B will have failed both a VEGF receptor inhibitor and an mTOR inhibitor. Evaluation of each group will be performed separately. The goals of this study are:

  1. To measure clinical benefit defined as an objective tumor response using RESIST or progression-free survival for more than 12 weeks in patients with metastatic carcinoma of the kidney who have failed or have progressed on a VEGF receptor inhibitor
  2. To evaluate the safety of perifosine in patients with metastatic carcinoma of the kidney who have failed or have progressed on a VEGF receptor inhibitor.

Treatment Phase/duration of treatment: All patients will be treated with daily perifosine at 100 mg PO daily until tumor progression (by the RECIST criteria) or unacceptable toxicity. Once radiological disease progression has been documented by the treating physician, the patient will go off study. Patients are encouraged to have two measurements for confirmation of progression.

Follow-Up Phase: All patients will be followed-up for SAEs until at least 30 days after discontinuation of perifosine. All patients who are discontinued from perifosine for any reason other than disease progression will continue to have tumor assessments until the patient has documented disease progression or has begun other therapies.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with confirmed metastatic RCC
  • Patients must have documented progression on treatment with sunitinib or sorafenib. Prior therapy with bevacizumab and/or cytokines (i.e., IL-2, interferon) is permitted. Prior vaccine therapy in the adjuvant setting is also permitted. Patients can have failed therapy with ONE prior mTOR inhibitor.
  • Patients must have at least one measurable lesion on computer tomography (CT) Scan or magnetic resonance imaging (MRI) using Modified RECIST criteria.
  • Patients must have normal organ and marrow function, unless in the opinion of the treating investigator, the abnormality is related to tumor, and the study chairman agree the abnormality is unlikely to affect the safety of perifosine use. Normal organ and marrow function is described below:

    • ANC >= 1.5 x 109/L
    • Platelets >= 75,000/ mm3
    • HCT >= 28% (with or without growth factor support)
    • Creatinine <= 3.0 mg/dl
    • Total bilirubin <= 1.5 x upper limit of normal
    • Transaminase <= 2.5 x upper limit of normal
  • ECOG performance status of 0 or 1
  • Patients with CNS metastases must be clinically stable for at least 2 months following treatment with radiation therapy, surgery, or both; and be off corticosteroids and anti-seizure medication.
  • Patients with a life expectancy ≥6 months
  • Age ≥18 years old
  • Patients who give a written informed consent obtained according to local guidelines
  • Women of childbearing potential must have had a negative serum or urine pregnancy test 72 hours prior to the administration of the first study treatment.

Exclusion Criteria:

  • Patients who have not recovered (<= grade 1) from adverse events from prior therapy (excluding alopecia).
  • Patients currently receiving sorafenib or sunitinib who have received either of these within 2 weeks prior to study entry.
  • Patients may have had prior sorafenib OR sunitinib BUT cannot have been treated with both VEGF receptor inhibitors.
  • Patients with a known hypersensitivity to perifosine or its excipients.
  • Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods.
  • Patients who are using other investigational agents or who had received investigational drugs <= 4 weeks prior to study entry.
  • Patients unwilling to or unable to comply with the protocol.
  • Patients who have a history of another primary malignancy <= 5 years with the exceptions of non melanomatous skin cancer and carcinoma in situ of the cervix.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00498966

Locations
United States, Kentucky
Investigative Site
Louisville, Kentucky, United States, 40202
United States, New Jersey
Investigative Site
Morristown, New Jersey, United States, 07962
United States, New York
Investigative Site
Armonk, New York, United States, 10504
Sponsors and Collaborators
AEterna Zentaris
Investigators
Study Chair: Nicholas J Vogelzang, MD Nevada Cancer Institute
  More Information

No publications provided

Responsible Party: AEterna Zentaris
ClinicalTrials.gov Identifier: NCT00498966     History of Changes
Other Study ID Numbers: Perifosine 231
Study First Received: July 9, 2007
Last Updated: February 14, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by AEterna Zentaris:
Kidney
perifosine
Progression on treatment with sunitinib or sorafenib

Additional relevant MeSH terms:
Carcinoma, Renal Cell
Kidney Neoplasms
Adenocarcinoma
Carcinoma
Kidney Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms

ClinicalTrials.gov processed this record on November 20, 2014